Skip to main content
TipRanks
Go Ultimate75% OFF

AxoGen (0HKD) Share Price & Analysis

0 Followers

0HKD Stock Chart & Stats

$55.98$0.18(0.32%)
At close: 4:30 PM GMT
$40$50Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$54.99 - $57.02
52-Week Range
$23.30 - $59.46
Previous Close
$55.80
Volume
N/A
Average Volume (3M)
1,623
Market Cap
$3.34B
Enterprise Value
$2.25B
Total Cash (Recent Filing)
$348.07M
Total Debt (Recent Filing)
$19.47M
Price to Earnings (P/E)
―
Beta
1.44
Next Earnings
Feb 23, 2027 (Est.)
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth And Gross Margins

Strong revenue growth alongside consistently high gross margins indicates attractive product economics and expanding adoption of AxoGen’s peripheral nerve repair portfolio. These characteristics can support reinvestment, commercial expansion, and improving operating leverage as sales scale over the next several quarters.

Improving Cash Generation

The shift to positive operating and free cash flow is a meaningful quality improvement while AxoGen is still reporting accounting losses. Sustained cash generation would provide internally funded capacity for commercial investment and reduce reliance on external financing as the business grows.

Expanded Payer Coverage

Near-universal commercial coverage can reduce reimbursement barriers and support broader surgeon and hospital adoption of Avance. The addition of coverage across major insurers creates a more durable utilization foundation, strengthening demand potential across AxoGen’s established nerve-repair markets.

Bears Say

Persistent Unprofitability

AxoGen has not yet converted strong revenue growth and gross margins into durable GAAP profitability. Continued operating losses constrain retained capital, leave the company dependent on further scale improvements, and make sustained expense discipline essential for long-term earnings conversion.

Operating Cost And Margin Pressure

Higher product costs and sharply increased operating expenses are currently absorbing part of the benefit from revenue growth. If costs continue to scale faster than sales, margin expansion and the path to sustainable profitability could be delayed despite the company’s strong underlying demand.

BioCircuit Integration And Amortization Risk

The BioCircuit acquisition expands the portfolio but adds execution complexity, purchase-accounting effects, and recurring amortization and administrative costs. These burdens could dilute near-term earnings quality and delay expected synergies if product integration or commercial overlap proves more difficult than planned.

AxoGen News

0HKD FAQ

What was AxoGen’s price range in the past 12 months?
AxoGen lowest share price was $23.30 and its highest was $59.46 in the past 12 months.
What is AxoGen’s market cap?
AxoGen’s market cap is $3.34B.
When is AxoGen’s upcoming earnings report date?
AxoGen’s next earnings report is estimated for Feb 23, 2027 (not yet confirmed), which is in 99 days.
How were AxoGen’s earnings last quarter?
AxoGen released its earnings results on Oct 28, 2026. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.131 by $0.079.
Is AxoGen overvalued?
According to Wall Street analysts AxoGen’s price is currently Undervalued.
Does AxoGen pay dividends?
AxoGen pays a dividend of $0.285 which represents an annual dividend yield of ―. See more information on AxoGen dividends here
What is AxoGen’s EPS estimate?
AxoGen’s EPS estimate is 0.15.
How many shares outstanding does AxoGen have?
AxoGen has 59,730,717 shares outstanding.
What happened to AxoGen’s price movement after its last earnings report?
AxoGen reported an EPS of $0.21 in its last earnings report, beating expectations of $0.131. Following the earnings report the stock price went up 29.344%.
Which hedge fund is a major shareholder of AxoGen?
Hedge funds hold AxoGen shares: the largest hedge-fund position in AxoGen is 566,283,042 shares, and hedge funds increased their holdings by 24.7K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology